P. Neven

1.2k total citations
24 papers, 836 citations indexed

About

P. Neven is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, P. Neven has authored 24 papers receiving a total of 836 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Genetics and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in P. Neven's work include Estrogen and related hormone effects (8 papers), Ovarian cancer diagnosis and treatment (5 papers) and Advanced Breast Cancer Therapies (4 papers). P. Neven is often cited by papers focused on Estrogen and related hormone effects (8 papers), Ovarian cancer diagnosis and treatment (5 papers) and Advanced Breast Cancer Therapies (4 papers). P. Neven collaborates with scholars based in Belgium, United Kingdom and United States. P. Neven's co-authors include Giuseppe Floris, Gϋnter von Minckwitz, N. Davidson, Holger Eidtmann, Natasha Schenk, Richard de Boer, Robert E. Coleman, Nigel Bundred, J. Miller and Antonio Llombart‐Cussac and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

P. Neven

22 papers receiving 816 citations

Peers

P. Neven

ONCOL

PRM

GENET

Mila Pinchev Israel

D. G. Kieback Germany

Anne Irene Hagen Norway

Catherine Harper‐Wynne United Kingdom

Nigel Sacks United Kingdom

N.J. Bundred United Kingdom

Eduard Vrdoljak Croatia

G. Gademann Germany

S. Ashley United Kingdom

Mauro Porpiglia Italy

Mila Pinchev Israel

P. Neven

534 ×1.0

ONCOL

344 ×1.5

136 ×0.7

PRM

185 ×1.0

GENET

313 ×1.7

Citations per year, relative to P. Neven P. Neven (= 1×) peers Mila Pinchev

Countries citing papers authored by P. Neven

Since Specialization

Citations

This map shows the geographic impact of P. Neven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Neven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Neven more than expected).

Fields of papers citing papers by P. Neven

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Neven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Neven. The network helps show where P. Neven may publish in the future.

Co-authorship network of co-authors of P. Neven

This figure shows the co-authorship network connecting the top 25 collaborators of P. Neven. A scholar is included among the top collaborators of P. Neven based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Neven. P. Neven is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Neven, P., et al.. (2025). Fat-augmented latissimus dorsi flap and implant-based latissimus dorsi flap: A systematic review. Journal of Plastic Reconstructive & Aesthetic Surgery. 105. 136–147.

Baelen, Karen Van, Marion Maetens, Tatjana Geukens, et al.. (2024). Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review. Breast Cancer Research. 26(1). 81–81. 6 indexed citations

Schepper, Maxim De, Tatjana Geukens, Karen Van Baelen, et al.. (2024). Stromal Tumor-Infiltrating Lymphocytes in Hormone Receptor–Positive/HER2 Negative Metastatic Breast Cancer. Modern Pathology. 38(2). 100650–100650.

Vanderstichele, Adriaan, Liselore Loverix, Els Van Nieuwenhuysen, et al.. (2022). Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer. Gynecologic Oncology. 165(1). 14–22. 19 indexed citations

Vandecaveye, Vincent, Steven Pans, Raphaëla C. Dresen, et al.. (2021). Cancer surveillance in adults with germline TP53 pathogenic variants: A single-center observational study.. Journal of Clinical Oncology. 39(15_suppl). 10530–10530. 1 indexed citations

Leunen, Karin, et al.. (2017). Neoadjuvant Weekly Paclitaxel-Carboplatin Is Effective in Stage I-II Cervical Cancer. International Journal of Gynecological Cancer. 27(6). 1256–1260. 14 indexed citations

Jérusalem, Guy, Gabriella Mariani, Eva Ciruelos, et al.. (2016). Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). Annals of Oncology. 27(9). 1719–1725. 44 indexed citations

O’Shaughnessy, Joyce, Mario Campone, Étienne Brain, et al.. (2015). Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. Annals of Oncology. 27(1). 106–113. 54 indexed citations

Dezentjé, Vincent O., Frans L. Opdam, Hans Gelderblom, et al.. (2015). CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects. Breast Cancer Research and Treatment. 153(3). 583–590. 46 indexed citations

10.

Vulsteke, Christof, Alena M. Pfeil, Matthias Schwenkglenks, et al.. (2014). Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel. Breast Cancer Research and Treatment. 147(3). 557–570. 24 indexed citations

11.

Moerman, Ph., et al.. (2013). Primary invasive mucinous ovarian carcinoma of the intestinal type: Importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases. European Journal of Cancer. 49(7). 1600–1608. 57 indexed citations

12.

Azim, Hatem A., Stefan Michiels, Flora Zagouri, et al.. (2013). Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Annals of Oncology. 24(3). 647–654. 85 indexed citations

13.

Neven, P., et al.. (2012). Update on triple-negative breast cancer: prognosis and management strategies. International Journal of Women s Health. 4. 511–511. 114 indexed citations

14.

Loibl, Sibylle, et al.. (2010). Management of menopausal symptoms in breast cancer patients. Maturitas. 68(2). 148–154. 46 indexed citations

15.

Eidtmann, Holger, Richard de Boer, Nigel Bundred, et al.. (2010). Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Annals of Oncology. 21(11). 2188–2194. 229 indexed citations

16.

Neven, P., M. Drijkoningen, V. Van Belle, et al.. (2009). Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1. Journal of Clinical Pathology. 62(7). 624–628. 31 indexed citations

17.

Robertson, J.F.R., Guenther G. Steger, P. Neven, et al.. (2009). Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Annals of Oncology. 21(6). 1246–1253. 20 indexed citations

18.

Neven, P., Frédéric Amant, Patrick Berteloot, et al.. (2006). Endocrine Treatment and Prevention of Breast and Gynecological Cancers Vth International Symposium of the Flemish Gynecological Oncology Group, January 26?28, 2006. International Journal of Gynecological Cancer. 16(s2). 479–491. 1 indexed citations

19.

Neven, P., et al.. (2004). Endocrine treatment and prevention of breast and gynaecological cancers. European Journal of Cancer Supplements. 2(9). 1–14. 1 indexed citations

20.

Neven, P.. (2002). The origin of postmenopausal oestrogens. European Journal of Cancer. 38. 29–30. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact